▶also seen on http://canswersite.com and http://canswerist.com
Subscribe to this blog
Follow by Email
MYJ | Monitoring breakthroughs in cancer research
As a cancer survivor for nearly four years, I am always interested in reports of this type: "Much research involving whole-genome sequencing is aimed at finding differences in the individual letters that make up the genetic code. The belief is that those small alterations will point to molecular pathways that regulate disease, which would be potential targets for drug therapies." ___ SOURCE | http://tiny.cc/altacities130 ___ SEARCH | http://tiny.cc/altacities657 ___
In a fresh advance for the burgeoning field of personalized medicine, researchers have developed a blood test based on the DNA of tumors that could help tailor treatment for individual cancer patients.
The report, announced Thursday, represents one of the most tangible examples yet of how the ability to sequence a person's entire genetic code could have a direct impact on patient care. There have been a flurry of reports on new sequencing technology that is yielding enormous amounts of information about genetics and disease, but that has yet to deliver much in the way of new treatment strategies.
"For cancer patients there hasn't been much utility so far. This may prove to be one of the first useful approaches," said Victor Velculescu, co-director of the cancer biology program at Johns Hopkins University's Kimmel Cancer Center and senior author of the new study.
ACOR▶ a large collection of cancer-related online email lists, which has delivered millions of email messages to subscribers across the globe. https://goo.gl/mjrQ77
An INTRANET is a private network accessible only to an organization's staff or members. Generally a wide range of information and services from the organization's internal IT systems are available that would not be available to the public from the Internet. By function, ACORis an INTRANETsite.
When a #Canswerist (aka cancer survivor or caregiver) looks to begin or extend research for their diagnosis (DX), the world wide web (or internet) is a logical starting points. Typically, such a search may lead to discovery on a range of INTRANETS.
Bone marrow transplants, aka stem cell transplants (SCT) offer a second chance for people with life-threatening blood cancers and other hematologic malignancies. I know because I am one of the SCT success stories from the place known as City of Hope (COH).▶ COH performed its first bone marrow transplant in 1976. Since then, thousands of patients from virtually every state and dozens of countries have undergone bone marrow, cord blood or stem cell transplants at COH.▶ Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood.▶ It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from an identical twin).▶ It is a medical procedure in the field of hematology, most often performed for patients with certain cancers of the blood or bone marrow, such as multiple myeloma, lymphoma (my DX) or …
▶ Gradually, but surely, we are now archiving MyJournal posts in our G+ collection. Follow us there.
▶ First day of the winter solstice arrived yesterday and that generally means no real change in the weather conditions for Southern California, but we have finally had a few days of partly-cloudy rain to initiate the official changing of the seasons▶ Unfortunately and personally, the last few months have been mostly marked with prolonged and unrelenting respiratory distress, officially diagnosed last Friday as acute bronchitis.
▶ A new cocktail of medicines have been prescribed: 1) Ibratropium Bromide nasal spray; 2) Prednisone, a steroid; and 3) Benzonatate, a cough suppressant. All of this followed my third IVIG in three months since September at City of Hope, as that last procedure generally lasts me for six months, but not at this time. Immune system issues remain and underlying challenge in my ninth year post DX with mantle cell lymphoma and eight years post the allogeneic stem ce…